Clinical Trials

NCT Number: NCT06318273 Phase: PHASE1 Trial Summary: Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): AbbVie Acronym:

NCT Number: NCT06334432 Phase: PHASE1|PHASE2 Trial Summary: NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Nuvation Bio Inc. Acronym:

NCT Number: NCT06193486 Phase: PHASE1 Trial Summary: This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment options and are on zol – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): H. Lee Moffitt Cancer Center and […]

NCT Number: NCT06237179 Phase: PHASE1|PHASE2 Trial Summary: To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak & 6-minute walk distance [6MWD]) among prostate cancer (PC) patients – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Virginia Commonwealth University Acronym: EXTRA-PC

NCT Number: NCT06238479 Phase: PHASE1 Trial Summary: The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two pa – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Eli Lilly and Company […]

NCT Number: NCT06242470 Phase: PHASE1 Trial Summary: The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): MacroGenics Acronym:

NCT Number: NCT05948657 Phase: Trial Summary: This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermedi – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: ESCAPE

NCT Number: NCT06244004 Phase: PHASE2 Trial Summary: This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alo – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Northwestern University Acronym:

NCT Number: NCT06011499 Phase: Trial Summary: This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received andr – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): OHSU Knight Cancer Institute Acronym: iLIVE

NCT Number: NCT06257758 Phase: PHASE1|PHASE2 Trial Summary: The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers. There are two part – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Valerio Therapeutics Acronym: